Cargando…

CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells

Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is a new promising target for the treatment of ovarian cancer. Our previous study showed that cross‐reacting material 197 (CRM197), a specific HB‐EGF inhibitor, significantly reverses resistance against paclitaxel in paclitaxel‐resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xiao‐han, Li, Hui, Zheng, Xiu‐shuang, Lu, Mei‐song, An, Yuan, Zhang, Xiao‐lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797568/ https://www.ncbi.nlm.nih.gov/pubmed/31490008 http://dx.doi.org/10.1002/cam4.2512

Ejemplares similares

NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway
por: Jinawath, Natini, et al.
Publicado: (2009)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer
por: Feng, Lanlan, et al.
Publicado: (2020)

The association of resistance training with risk of ovarian cancer
por: Buras, Andrea L, et al.
Publicado: (2021)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Bioinformatic profiling identifies a platinum‐resistant–related risk signature for ovarian cancer
por: Wu, Ce, et al.
Publicado: (2019)

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer
por: He, Jing, et al.
Publicado: (2019)

FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world
por: Marschner, Norbert, et al.
Publicado: (2022)

Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer
por: Zhao, Meng-Dan, et al.
Publicado: (2019)

Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice
por: Chen, Xi, et al.
Publicado: (2016)

Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells
por: Fan, Li-li, et al.
Publicado: (2020)

Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment
por: Craveiro, Vinicius, et al.
Publicado: (2013)

The clinical implication of CD45RA(+) naïve T cells and CD45RO(+) memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction
por: Hang, Junjie, et al.
Publicado: (2019)

Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells
por: Weiner-Gorzel, Karolina, et al.
Publicado: (2015)

Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer
por: Niu, Xiaxia, et al.
Publicado: (2022)

Gadd45β and Gadd45γ are critical for regulating autoimmunity
por: Liu, Lin, et al.
Publicado: (2005)

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Investigating the Deoxyribonuclease Activity of CRM197 with Site-Directed Mutagenesis
por: Bravo-Bautista, Nathalie, et al.
Publicado: (2019)

Cold Atmospheric Plasma Restores Paclitaxel Sensitivity to Paclitaxel-Resistant Breast Cancer Cells by Reversing Expression of Resistance-Related Genes
por: Park, Sungbin, et al.
Publicado: (2019)

The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model
por: Papaevangelou, Efthymia, et al.
Publicado: (2018)

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
por: Duan, Zhenfeng, et al.
Publicado: (2014)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
por: Borghese, Cinzia, et al.
Publicado: (2020)

O:2-CRM(197) Conjugates against Salmonella Paratyphi A
por: Micoli, Francesca, et al.
Publicado: (2012)

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)‐mutant resistance in vitro and in vivo
por: Zhang, Zhang, et al.
Publicado: (2018)

Associations of insulin resistance and inflammatory biomarkers with endometrial cancer survival: The Alberta endometrial cancer cohort study
por: Morielli, Andria R., et al.
Publicado: (2022)

Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429
por: Guo, Qinglong, et al.
Publicado: (2018)

Recreational physical activity and ovarian cancer risk in African American women
por: Abbott, Sarah E., et al.
Publicado: (2016)

Detection of early stage ovarian cancer in a large community cohort
por: Suh‐Burgmann, Elizabeth J., et al.
Publicado: (2019)

The role of D-GADD45 in oxidative, thermal and genotoxic stress resistance
por: Moskalev, Alexey, et al.
Publicado: (2012)

Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing
por: Greenberg, Samantha, et al.
Publicado: (2019)

Knockdown of GINS2 inhibits proliferation and promotes apoptosis through the p53/GADD45A pathway in non-small-cell lung cancer
por: Chi, Feng, et al.
Publicado: (2020)

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
por: Zhang, Xin, et al.
Publicado: (2022)

Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma
por: Kobayashi, Hiroki, et al.
Publicado: (2020)

Double-edged Gadd45
por: Powell, Kendall
Publicado: (2005)

Gadd45 in stress signaling
por: Liebermann, Dan A, et al.
Publicado: (2008)

Epithelial ovarian cancer subtypes attributable to smoking in the Norwegian Women and Cancer Study, 2012
por: Licaj, Idlir, et al.
Publicado: (2016)

Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance
por: Lei, Meng, et al.
Publicado: (2019)

Age at menarche and epithelial ovarian cancer risk: A meta‐analysis and Mendelian randomization study
por: Yang, Huijun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q64e2afnristapdv02t9m6vm9h